X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with IPCA Labs - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA IPCA LABS SHASUN PHARMA/
IPCA LABS
 
P/E (TTM) x 123.9 33.0 376.0% View Chart
P/BV x 8.5 2.5 337.7% View Chart
Dividend Yield % 0.2 0.2 114.6%  

Financials

 SHASUN PHARMA   IPCA LABS
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
IPCA LABS
Mar-17
SHASUN PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs94643 14.7%   
Low Rs46503 9.1%   
Sales per share (Unadj.) Rs214.2254.4 84.2%  
Earnings per share (Unadj.) Rs5.316.1 33.2%  
Cash flow per share (Unadj.) Rs15.829.8 53.1%  
Dividends per share (Unadj.) Rs1.001.00 100.0%  
Dividend yield (eoy) %1.40.2 819.6%  
Book value per share (Unadj.) Rs53.3194.6 27.4%  
Shares outstanding (eoy) m56.62126.20 44.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.3 14.5%   
Avg P/E ratio x13.135.7 36.7%  
P/CF ratio (eoy) x4.419.2 23.0%  
Price / Book Value ratio x1.32.9 44.5%  
Dividend payout %18.76.2 301.2%   
Avg Mkt Cap Rs m3,95872,300 5.5%   
No. of employees `000NA13.3 0.0%   
Total wages/salary Rs m2,1646,960 31.1%   
Avg. sales/employee Rs ThNM2,413.5-  
Avg. wages/employee Rs ThNM523.2-  
Avg. net profit/employee Rs ThNM152.4-  
INCOME DATA
Net Sales Rs m12,12732,106 37.8%  
Other income Rs m229226 101.6%   
Total revenues Rs m12,35632,332 38.2%   
Gross profit Rs m1,0094,448 22.7%  
Depreciation Rs m5941,730 34.3%   
Interest Rs m415241 172.4%   
Profit before tax Rs m2302,703 8.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-73675 -10.8%   
Profit after tax Rs m3022,028 14.9%  
Gross profit margin %8.313.9 60.1%  
Effective tax rate %-31.725.0 -126.7%   
Net profit margin %2.56.3 39.4%  
BALANCE SHEET DATA
Current assets Rs m6,88417,340 39.7%   
Current liabilities Rs m8,4569,559 88.5%   
Net working cap to sales %-13.024.2 -53.5%  
Current ratio x0.81.8 44.9%  
Inventory Days Days62100 61.4%  
Debtors Days Days10857 189.1%  
Net fixed assets Rs m4,97020,779 23.9%   
Share capital Rs m113252 44.9%   
"Free" reserves Rs m2,87524,499 11.7%   
Net worth Rs m3,02024,553 12.3%   
Long term debt Rs m1,8173,517 51.7%   
Total assets Rs m13,34739,595 33.7%  
Interest coverage x1.612.2 12.7%   
Debt to equity ratio x0.60.1 420.0%  
Sales to assets ratio x0.90.8 112.1%   
Return on assets %5.45.7 93.8%  
Return on equity %10.08.3 121.1%  
Return on capital %13.310.5 127.0%  
Exports to sales %46.448.6 95.3%   
Imports to sales %14.214.2 100.1%   
Exports (fob) Rs m5,62215,617 36.0%   
Imports (cif) Rs m1,7284,571 37.8%   
Fx inflow Rs m5,84315,617 37.4%   
Fx outflow Rs m2,1735,828 37.3%   
Net fx Rs m3,6699,790 37.5%   
CASH FLOW
From Operations Rs m3982,764 14.4%  
From Investments Rs m-1,635-1,432 114.2%  
From Financial Activity Rs m1,309-1,591 -82.2%  
Net Cashflow Rs m71-259 -27.5%  

Share Holding

Indian Promoters % 39.2 45.9 85.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 11.4 31.6%  
FIIs % 17.6 25.3 69.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 17.4 227.6%  
Shareholders   20,750 36,892 56.2%  
Pledged promoter(s) holding % 12.3 2.1 574.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   ALKEM LABORATORIES  PLETHICO PHARMA  WOCKHARDT LTD.  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare SHASUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Share Markets in India End Flat; Dr Reddy's & Tata Steel Top Gainers(Closing)

Indian share markets continued to trade range bound in afternoon session with market participants awaiting the US Federal Reserve's policy statement.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

India's Big and Messy Real Estate Ponzi Scheme, Just Got Messier(Vivek Kaul's Diary)

Sep 11, 2017

The question is, whether real estate buyers are financial creditors or not.

180,000%: The Returns That Could Have Been(The 5 Minute Wrapup)

Sep 7, 2017

For successful investing in small caps, it's important to know when not to press the panic button.

Feeling Left Out? Two Opportunities to Make Money in This Market(Daily Profit Hunter)

Sep 13, 2017

Nifty is above 10,000 once again. Have you missed the bus?

Introducing Smart Contrarian: The Blueprint for Big Profits from Small Investments

Sep 18, 2017

Welcome to a bold, new initiative designed for the truly contrarian investor.

How To Link Aadhaar With Your Mutual Fund Investments(Outside View)

Sep 11, 2017

The Government has extended the linking of the unique Aadhaar number to nearly all financial transactions.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA - DIVIS LABORATORIES COMPARISON

COMPARE SHASUN PHARMA WITH

MARKET STATS